- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
MassBio Releases Five-Year Plan for Future Direction of Massachusetts Life Sciences Ecosystem
The Massachusetts Biotechnology Council (MassBio) today released its State of Possible 2025 Report, a five-year strategic plan to define the future direction of the Massachusetts life sciences ecosystem and highlight the many systemic challenges that require attention for the cluster to stay ahead of the curve on scientific innovation. The report will also serve as a call to action to drive cross-industry collaboration in order to overcome shared challenges, capitalize on Massachusetts’ greatest assets, and develop strategic economic development.
Through interviews and consultations with government, academic, and industry leaders, this report, prepared by Deloitte, found that the Massachusetts life sciences community is expected to achieve balanced growth over the next five years. Some of the areas include expanding R&D beyond oncology and rare diseases as well as positioning the state as a center for medical technology.
The report also calls attention to some gaps for improvement needed for the industry to thrive and grow sustainably. Some of these gaps are the availability of funding and the lack of affordable space and an efficient transportation system.
For more information on the full report, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
